SCHEMBL23958665

SCHEMBL23958665

COC(=O)c1cc(OC)c2ncc(C(F)F)cc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.43
HPGDS O60760 1/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 1/20 0.42
PSMD14 O00487 1/20 0.40
PTPN11 Q06124 1/20 0.38
MAPT P10636 2/20 0.38
CNR2 P34972 1/20 0.36
ALOX15 P16050 1/20 0.35
HTT P42858 1/20 0.35
TSHR P16473 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
KMT2A Q03164 2/20 0.35
POLB P06746 2/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23904767 0.88 CA12 (0.44) HPGDSKDM4ECNR2HTTTSHR
SCHEMBL30006877 0.88 CA12 (0.44) HPGDSKDM4ECNR2HTTTSHR
SCHEMBL23958826 0.85 HPGDS (0.38) HPGDSKDM4EL3MBTL1
SCHEMBL31125819 0.83 CYP3A4 (0.40) CYP3A4HPGDSKDM4EALDH1A1PSMD14
SCHEMBL23883090 0.82 ALDH1A1 (0.45) CYP3A4HPGDSKDM4EALDH1A1PSMD14
SCHEMBL23905372 0.82 KDM4E (0.45) CYP3A4HPGDSKDM4EALDH1A1PSMD14
SCHEMBL23905404 0.81 ATM (0.47) CYP3A4HPGDSKDM4EALDH1A1PSMD14
SCHEMBL23904892 0.81 KDM4E (0.46) CYP3A4HPGDSKDM4EALDH1A1PSMD14
SCHEMBL23883070 0.81 KDM4E (0.46) CYP3A4HPGDSKDM4EALDH1A1PSMD14
SCHEMBL23166783 0.80 KDM4E (0.45) CYP3A4HPGDSKDM4EALDH1A1PSMD14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
CN-115461336-A RSV inhibiting 3-substituted quinoline and cinnoline derivatives 爱尔兰詹森科学公司 2022-12-09 CN disclosed
WO-2021214136-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES ACE2, SIRT7, ACE CYP3A4 398/4885HPGDS 4259/4885KDM4E 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.